The journal became open access, online-only, and fully searchable and accessible through PubMed. Submission and publishing fees have been waived ever since. The types of manuscripts were streamlined to editorial comments, ckj reviews, original articles and exceptional case reports.
Over the past 4 years, the number of published items decreased when compared with the younger ckj ( Figure 1A ). This was a consequence of a higher quality threshold for publication. Thus, the number of submissions was 449 in 2015 and is expected to hover around 480 in 2018. However, the acceptance rate decreased from 40% in 2013 to 36% in 2015 and 26% in 2018. The types of manuscripts published shifted to an increase of high-quality ckj reviews and original manuscripts. These changes were well received by the nephrological community and the number of citations per year exponentially increased ( Figure 1B ). In 2016, ckj was accepted for indexing in the new Emerging Sources Citation Index (ESCI) database from Clarivate Analytics (previously Thomson Reuters). From January 2019 it will be listed in the full Science Citation Index. ckj will therefore receive its first official impact factor based upon 2018 citation to 2016 and 2017 articles. While no official impact factor was awarded for 2017, the estimated impact factor calculated from data available in Clarivate's Web of Science database rose to 2.987 in 2017 (Figure 2A ). In this regard, it is estimated that ckj is approaching the first quartile (Q1, 25% top journals as assessed by impact factor) in the Urology and Nephrology field ( Figure 2B ). In the 2017 impact factor database, released in June 2018, there were 10 Urology and 9 Nephrology journals in Q1. Of the latter, only five published original manuscripts.
ckj has become a global reference for practicing nephrologists. The main geographical origin of submissions is the USA (22-25% across 2015-18). On the other side of the coin, the top five user countries were, in this order, USA, Great Britain, India, Canada and Australia. However, there were users from a total of 210 countries in 2018, making it a truly global journal (Figure 3) .
The most cited manuscripts in this new era are listed in Tables 1-3 . Over the past 4 years, the most cited items were ERA-EDTA Registry reports and systematic reviews ( (Table 3) . Among the most cited topics, we find systematic reviews and meta-analysis on exercise, vitamins K and D, and assessment of renal function and injury, including the use of a urine peptidomics-based marker of kidney injury recently refined to beat glomerular filtration rate and urinary albumin:creatinine ratio for prediction of chronic kidney disease (CKD) progression when the estimated glomerular filtration rate is still not diagnostic of CKD [46] . Other topics that drew the attention of authors were onconephrology, the interrelationship of the gut microbiota and kidney disease, low-protein diets, residual renal function, eculizumab, sustainability of renal replacement therapy, socioeconomic and psychosocial factors and gender impact on CKD, CKD hotspots, management of hyperphosphataemia, hyperkalaemia, hyperuricaemia and acute kidney injury (AKI). Many topics were shared with the 100 most cited papers in nephrology, presented in this issue of ckj, suggesting overall clinical interest for the nephrological community. Shared topics include renal function assessment, pharmacology, dialysis/transplantation, AKI and CKD [47] .
In contrast, the top downloaded articles were very practical in approach and included the 2017 update on pain management in patients with CKD [48] and a manuscript on palliative care for patients with end-stage renal disease [49] , both published in 2017. In 2018, the top downloaded articles dealt with high-dose vitamin K for calciphylaxis [50] , therapy of childhood C3 glomerulopathy [51] and hyponatraemia in kidney transplant patients [52] .
A different vision of the impact of ckj is provided by the Altmetrics score. In 2018, the three top manuscripts dealt with the 'ExTra CKD' trial of supervised exercise in CKD [53] , living kidney donor use of marijuana [54] and the EMPA-KIDNEY study of sodium/glucose cotransporter 2 (SGLT2) inhibitors in CKD [55] .
As part of our focus on education, ckj has started a collaboration with GlomCon and the ERA-EDTA Young Nephrologists' Platform in 2018. Up to now, two ckj manuscripts have been discussed in the Journal Club webinar with active participation of the Editor-in-Chief and in some cases of the authors [56, 57] . For 2019, the manuscript 'Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network' by Sprangers et al. [58] is scheduled to be discussed on 7 May 2019. [39%]
[37%] Hopefully, we will relay to the next Editor-in-Chief, to be elected in 2021, an internationally renowned journal that continues to be a required and useful read for nephrologists intraining and practicing nephrologists. Raimann et al. [42] 3 Lung ultrasonography in end-stage renal disease: moving from evidence to practice-a narrative review
Ross et al. [43] 3 Cardiovascular effects of metabolic syndrome after transplantation: convergence of obesity and transplant-related factors.
Sgambat et al. [44] 3 MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? Selvaskandan et al. [45] Note: As of 18 December 2018, according to Web of Science.
